Evidence Snapshot

PDE5A/PDE6C

CHEMBL4523626 CHIMERIC PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:38:17Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:38 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL4523626

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats PDE5A/PDE6C as ChEMBL target CHEMBL4523626, mapped to UniProt O76074. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

PDE5A/PDE6C

CHIMERIC PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL4523626

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

O76074

cGMP-specific 3',5'-cyclic phosphodiesterase

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why PDE5A/PDE6C matters

As of 2026-09-13

PDE5A/PDE6C is reviewed as cGMP-specific 3',5'-cyclic phosphodiesterase (UniProt O76074); the current evidence base includes 1 approved drug, 2 compounds, and 1 assay, with lead potency reaching pChEMBL 7.6.

Protein context

cGMP-specific 3',5'-cyclic phosphodiesterase

cGMP-specific 3',5'-cyclic phosphodiesterase Sequence length is 875 aa.

Review this target as PDE5A/PDE6C, mapped to UniProt O76074. ChEMBL maps the protein component as cGMP-specific 3',5'-cyclic phosphodiesterase. Sequence length is 875 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt O76074 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 2 compounds, and 1 assay for this target. The dominant activity type is KI. CHEMBL192 is the current potency anchor at pChEMBL 7.6.

Use CHEMBL192 as the tractability anchor when discussing potency (pChEMBL 7.6).

Activity source · ChEMBL 36 via Core Engine

1 approved pChEMBL 7.6

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why PDE5A/PDE6C matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O76074, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

KI: 2.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure	Compound	pChEMBL	Type	Phase
	No preferred name CHEMBL192	7.6	Ki	Approved
	No preferred name CHEMBL275084	5.1	Ki	—